Novo Nordisk selects first drug candidate in Dicerna collaboration

Danish Novo Nordisk has selected its first drug candidate for the collaboration with Dicerna.

Novo Nordisk's Senior Vice President, Head of Global Drug Discovery Marcus Schindler. | Photo: Novo Nordisk / PR

Danish pharmaceutical giant Novo Nordisk has nominated its first drug candidate for the firm's collaboration with US pharmaceutical firm Dicerna, according to Danish business media Finans' information on the basis of a Dicerna press release.

In 2019, Novo Nordisk and Dicerna entered into a collaborative agreement to develop drugs focusing on the treatment of liver-related cardiovascular diseases such as non-alcoholic fatty liver, obesity and diabetes, for which occasion Novo Nordisk initially paid USD 175m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs